HD until they announce Celgro nerve approval
to market in US, IMO there will be no sustained
increase in share price for OCC. Might get a
temporary bump when TGA approve Celgro
nerve in Aust or when ATI trial results are
released,(if that ever happens and the results
are very good).
I think some shareholders are too optimistic
for anything other than modest returns from
Striate. They can’t even organise a distributor
in the US. Did someone mention sales of
$20M next 12 months or was it in 12 months time.
Tell ‘im he’s dreamin’.
OCC Trading, page-694
-
- There are more pages in this discussion • 1,018 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.31M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 35.5¢ | $65.26K | 181.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 56760 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 15.04pm 28/06/2024 (20 minute delay) ? |
| OCC (ASX) Chart |